Outlook Therapeuticsの空売り状況は、投資家がOutlook Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Outlook Therapeutics (NASDAQ:OTLK) 株価情報, 空売り情報

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Scotiabank analyst Divya Goyal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Sector Outperform and lowers the price target from $250 to $200.

News

Price Target

Analyst Ratings

EPAM

Scotiabank Maintains Sector Outperform on EPAM Systems, Lowers Price Target to $200

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) has outperformed the market over the past 5 years by 9.06% on an annualized basis producing an average annual return of 23.33%. Currently, Johnson Controls Intl has a market capitalization of $53.59 billion. 
Buying $1000 In JCI: If an investor had bought $1000 of JCI stock 5 years ago, it would be worth $2,921.39 today based on a price of $81.18 for JCI at the time of writing.
<h3>Johnson Controls Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745940623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Johnson Controls Intl Stock In The Last 5 Years

Scotiabank analyst Divya Goyal maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Sector Perform and lowers the price target from C$2.8 to C$2.5.

TSX:ALYA

Scotiabank Maintains Sector Perform on Alithya Group, Lowers Price Target to C$2.5

WIIM

Smithfield Foods shares are trading higher following a Q1 EPS and revenue beat.

CNO Financial Group shares are trading lower after the company reported Q1 financial results.

UFPI

UFP Industries shares are trading lower after the company reported worse-than-expected Q1 financial results.

Crane shares are trading higher after the company reported better-than-expected Q1 financial results. Also, UBS upgraded the stock from Neutral to Buy and raised its price target from $157 to $190.

FELE

Franklin Electric shares are trading lower after the company reported Q1 financial results and missed its EPS and revenue estimates.

JP Morgan analyst Domingos Falavina maintains Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) with a Overweight and lowers the price target from $15 to $13.5.

VINP

JP Morgan Maintains Overweight on Vinci Partners Inv, Lowers Price Target to $13.5

LifeMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares are trading higher Tuesday after the company announced it will offer <a href="https://www.benzinga.com//node/45064487">access to Wegovy.</a>
What To Know: LifeMD said it will offer access to Wegovy through Novocare Pharmacy, allowing the company to provide the weight-loss drug at a lower self-pay price of $499 per month.
The company said this offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options.
&#8220;By embedding direct access to Wegovy&nbsp;via NovoCare Pharmacy into our platform, we&#8217;re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD&#8217;s position as a leader in delivering comprehensive, technology-enabled obesity care,&#8221; said Justin Schreiber, Chairman and CEO of LifeMD.
Related Link: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45067829/microsoft-q3-earnings-azure-may-rise-30-thats-not-where-ctos-are-aggressively-spending-analyst-warns">Microsoft Q3 Earnings: Azure May Rise 30% &#8211; That&#8217;s Not Where &#8216;CTOs Are Aggressively Spending&#8217; Analyst Warns</a>
LFMD Price Action: At the time of writing, LifeMD shares are trading 19.8% higher at $7.31, according to data from Benzinga Pro.
Image: via Shutterstock

Movers

LFMD

LifeMD Stock Pops As Company Expands Weight-Loss Offerings With Wegovy

VKTX

Viking Therapeutics shares are trading higher after Cantor FItzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $104.

Investment Summary
Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) is a leading online platform where users can shop products. The company has been successful in harnessing the power of AI that has delivered benefits to all of its stakeholders – customers, advertisers and the business internally. Moreover, transformation of its ad platform has helped the company to deliver a record quarter with over $1 billion in revenues. The company's international business, which is growing at a stellar pace compared to its US business holds promise to deliver future growth. Our fair value estimate for the stock is $36.00.
Overview
Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) is an online platform for visual search and discovery that helps its users to find inspiration, curate ideas and shop products. The company boasts of around half a billion monthly active users globally.
Several AI-based initiatives delivering significant benefits
In the last one year, PINS has undertaken several AI-based initiatives, that have delivered significant benefits. In our view, these initiatives have benefited all the stakeholders such as customers, advertisers and the business internally.
First, PINS has managed to increase the context that feeds into the AI model based on&nbsp;<a href="https://s204.q4cdn.com/369458543/files/doc_earnings/2024/q4/transcript/Q4-2024-Transcript.pdf" target="_blank" rel="noreferrer noopener">saves and clicks by 30-fold.&nbsp;</a>More powerful ML models mean better understanding of the content the customers might enjoy. We believe this has delivered significant results as evidenced by 250 bps increase in saves and 150 bps increase in outbound clicks. Moreover, this has been achieved with minimal increase in the infrastructure spend.
Second, on the monetization side, AI has helped deliver relevant ad loads to the users. In the lower funnel phase of shopping journey more ads are displayed while a few in the upper funnel of the discovery phase. This has resulted in doubling of relevance for top ad slots.
Third, is use of AI by internal engineering teams to enhance productivity. The teams use coding assistants and around 15% of the code is generated through AI.
Lastly, AI has delivered results for advertisers in terms of better performance and efficiency by automating much of the campaign process.
In our view, PINS is well positioned to harness the benefits of AI across its business processes.
Transformation of Ad Platform improves monetization and benefits advertisers
PINS has successfully managed to transform its ad platform, that in our view, not only improves monetization but also delivers several benefits to the advertisers.
In terms of lower funnel launches, PINS helped users directly access advertisers web or mobile property, thereby significantly increasing the clicks. Moreover, it used privacy centric measurement tools enabling the advertisers to accurately measure the spend.
Moreover, it launched promotional ads to highlight special offers during key promotional periods. This has resulted in 18% increase in conversion rate as compared to ads without promotion.
Further, PINS has helped advertisers to automate their campaigns and improve performance through lower CPCs and CPAs.
We believe these steps have delivered significant results. PINS has manged to report a record quarter with more than $1 billion in revenue in a single quarter underpinned by strong ad platform. Moreover, the company witnessed record revenues during cyber 5 holiday while lowering CPAs by 30% YOY.
International business &#8211; the next growth engine
With a 22% share of overall revenues for 4Q24, in our view, the international business holds promise to become the next growth engine for PINS.
The company's international business – both Europe and Rest of the World have delivered stellar performance as compared to the core US and Canada business. In terms of topline growth, Europe segment grew by 21% YOY during 4Q24 and RoW increased by a solid 44% as compared to just 16% for US and Canada.
Moreover, the MAU growth for Europe was strong at 7% and RoW reported 15% growth that is significantly better than 4% for US and Canada. Likewise, the ARPU growth for RoW was 24% that was almost double than 12% for US and Canada.
The company has entered into partnerships with Amazon Ads and Google and launched resellers in over 30 markets. In our view, these efforts are paying off as evidenced by solid topline growth for RoW throughout 2024.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="976" height="296" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1.png" alt="" class="wp-image-11821" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1.png 976w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1-300x91.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1-768x233.png 768w" sizes="(max-width: 976px) 100vw, 976px" /><figcaption class="wp-element-caption">Source: Company filings</figcaption></figure>
Share Buyback to Limit Downside
In November 2024, Pinterest announced&nbsp;<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1506293/000150629324000182/pins-20240930.htm" target="_blank" rel="noreferrer noopener">a $2 billion share repurchase program</a>. Now, I consider this significant given the fact that this represents nearly 12% of the Company's current market capitalization. In our opinion, the large share repurchase program also implies that the management is confident of generating significant free cash flow going forward. If executed well, the buyback has the potential to not only limit the price downside but enhance return for the shareholders.
Financial Projections
In our view, PINS will be able to deliver low-teens topline growth for FY25-26 driven by the strength of its international business. We expect margins to expand as Pinterest leverages its fixed costs and drive operational efficiencies. As such, we are modelling EBITDA margins to improve from 28% in FY24 to 30% in FY25. Factoring in net interest income of $108 million and tax rate of nearly 21%, leads me to diluted EPS of $1.55 for FY 2025. For 2026, we expect sales growth of 12% YOY, and an EBITDA margin of 32%. This leads to diluted EPS of $1.83 for 2026.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="465" height="308" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2.png" alt="" class="wp-image-11824" style="width:484px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2.png 465w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2-300x199.png 300w" sizes="(max-width: 465px) 100vw, 465px" /></figure>
Valuation
For valuation purposes, we are using P/E relative valuation to arrive at the fair value of PINS.
We have compared PINS with some of its peers. We value PINS using target multiple of 19.4x on P/E method, in line with the peer group average. Important to note that, PINS is growing faster than many of its peers over 2024-26e and as such should command a multiple at least in line with the peer group average. Based on 2026e EPS of $1.83, the fair value estimate stands at $36.00.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="596" height="200" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3.png" alt="" class="wp-image-11825" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3.png 596w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3-300x101.png 300w" sizes="(max-width: 596px) 100vw, 596px" /></figure>
Risks
Below are the main risks to our investment thesis:
<ul>
<li>Given that PINS generates substantially all of its revenue from advertising, any macroeconomic slowdown could hurt its growth prospects. Dependence of key categories such as consumer packaged goods and retail also remains a risk.</li>
<li>We see third-party reliance risks especially high dependence on Amazon AWS. PINS uses AWS for majority of compute, storage and data transfer. As such any disruption to the AWS services could negatively impact PINS operations.</li>
<li>High competitive intensity is a risk. The company competes with several large and well-established players such as Amazon and Google. However, we believe that PINS' focus on AI-driven personalization and ad targeting capabilities could help it mitigate rising competitive intensity.</li>
</ul>
Disclaimer
This report is based on information we consider reliable, including the subject of the report. This report does not explicitly or implicitly affirm that the information contained within this document is accurate and/or comprehensive, and as such should not be relied on in such a capacity. All information contained within this report is subject to change without any formal or other notice provided.
This document does neither constitute an offer nor a request to buy or sell any securities. It only serves informational purposes. This report does not consider individual circumstances and does not take into consideration individual investor preferences. Recipients of this report should consult professionals around their personal situation, including taxation. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in equities.
GSBR Research has not received any compensation for this article. We do not own any stock holdings nor do we have plans to purchase the shares in the next 72 hours.

Equities

Long Ideas

Retail Sales

Opinion

Media

PINS

An Under the Radar Stock With 35%+ Upside Potential

Insperity shares are trading lower after the company reported worse-than-expected Q1 financial results, cut its FY25 adjusted EPS guidance, and issued Q2 adjusted EPS guidance below estimates.

JP Morgan analyst Bill Peterson maintains Teck Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Overweight and lowers the price target from C$58 to C$57.

TSX:TECK

TSX:TECK/B

JP Morgan Maintains Overweight on Teck Resources, Lowers Price Target to C$57

ON Semiconductor shares are trading lower after UBS cut its price target on the stock from $55 to $40.

Woodward shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance. Additionally, UBS raised its price target on the stock from $200 to $220.

The U.S. posted its widest monthly goods trade deficit on record in March, as companies rushed to import foreign goods ahead of sweeping tariffs set by President Donald Trump on what <a href="https://www.benzinga.com/topic/donald-trump">he dubbed as &#8220;Liberation Day.&#8221;</a>
The U.S. goods trade deficit widened to $161.9 billion in March 2025, up from $147.8 billion in February and smashing past Wall Street's $145 billion estimate, according to Commerce Department data released Tuesday.
<h3 class="wp-block-heading">Imports Surge Before Tariffs Kick In</h3>
U.S. businesses scrambled to stockpile everything from machinery to consumer electronics before the tariffs took effect.
Imports skyrocketed to $342.7 billion, up 5% month-on-month, but more strikingly, they were up 30.8% compared to March 2024—highlighting the urgency with which U.S. companies accelerated purchases of overseas goods.
Consumer goods led the surge, jumping 27.5% on the month and a staggering 55.5% over the year, to reach $102.8 billion. Imports of industrial supplies such as metals and chemicals climbed 13.5% month-on-month and 37.8% year-on-year, totaling $74.6 billion. Capital goods—machinery and equipment used for production—rose 3.8% to $92.8 billion, a 22.2% increase from a year ago. Automotive imports gained 6.6% to $41 billion.
 "The goods trade deficit continued to blow out in March,&#8221; wrote Liz Ann Sonders, chief investment strategist at Charles Schwab &amp; Co., on social media X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Goods trade deficit continued to blow out in March … new record high at $162 billion vs. $145 billion est. &amp; $147.9 billion prior <a href="https://t.co/gOW2DthZ8H">pic.twitter.com/gOW2DthZ8H</a>
&mdash; Liz Ann Sonders (@LizAnnSonders) <a href="https://twitter.com/LizAnnSonders/status/1917196666622398839?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Exports Rise, But Can't Keep Up</h3>
On the export side, the numbers improved, but not nearly enough to offset the import wave.
Total exports rose 1.2% from February and 6.8% year-over-year, reaching $180.8 billion. That modest gain was led by automotive vehicles, up 7.9% from February, industrial supplies, up 3%, and foods, feeds and beverages, up 6.9%.
However, consumer goods exports fell slightly by 1.1% to $21.8 billion, signaling that overseas demand may not be as robust as the domestic race to import.
Overall, the imbalance between export and import growth underscores how skewed the U.S. trade flow became in anticipation of tariffs. While export growth was steady, it paled in comparison to the aggressive import buildup.
<h3 class="wp-block-heading">Historical Context: Largest Goods Deficit Ever</h3>
The March 2025 trade balance dwarfed last year's levels. The $161.9 billion shortfall compares to a $92.8 billion deficit in March 2024, a 74.6% year-over-year increase. 
That margin highlights the extent to which policy uncertainty can shake up international commerce and distort monthly trade flows.
This is the largest U.S. goods trade deficit ever recorded, surpassing pandemic-era levels when global supply chains were disrupted but demand remained elevated.
<h3 class="wp-block-heading">Wall Street Reaction Muted</h3>
Markets reacted little to trade data as the front-loading frenzy was widely anticipated by analysts following Trump&#8217;s tariff announcement.
Corporate earnings guidance and the latest business survey throughout had already signaled the rush to import ahead of tariffs.
The S&amp;P 500 Index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – opened 0.4% lower at 5,510 points. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45059743/china-open-to-co-operate-with-us-firms-voices-concern-over-trade-war-impact-as-tariffs-hits-chinese-airlines-and-boeing">China Breaks Silence On Tariff Impact, Says Trump Policies Are Hurting Its Airlines And Boeing</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

US Trade Deficit Explodes To Record $162 Billion In March As Import Frenzy Precedes Trump's Tariff Barrage

General

AREB

American Rebel Holdings Shares Resume Trading

ARCC

Ares Capital shares are trading lower after the company reported worse-than-expected Q1 financial results.

JP Morgan analyst Rachel Vatnsdal maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Neutral and lowers the price target from $120 to $100.

RVTY

JP Morgan Maintains Neutral on Revvity, Lowers Price Target to $100

Press Releases

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Management

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment

Earnings

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

Outlook Therapeutics® Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Health Care

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Comments

Outlook Therapeutics

空売り

Outlook Therapeutics (NASDAQ:OTLK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル